Tonix Pharmaceuticals Holding (Tonix Pharmaceuticals Holding) Cyclically Adjusted PS Ratio : 0.37 (As of May. 26, 2024)

View and export this data going back to 2009. Start your Free Trial

What is Tonix Pharmaceuticals Holding Cyclically Adjusted PS Ratio?

As of today (2024-05-26), Tonix Pharmaceuticals Holding's current share price is $0.1755. Tonix Pharmaceuticals Holding's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $0.48. Tonix Pharmaceuticals Holding's Cyclically Adjusted PS Ratio for today is 0.37.

The historical rank and industry rank for Tonix Pharmaceuticals Holding's Cyclically Adjusted PS Ratio or its related term are showing as below:

TNXP' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.29 Med: 0.47 Max: 0.59
Current: 0.37

During the past years, Tonix Pharmaceuticals Holding's highest Cyclically Adjusted PS Ratio was 0.59. The lowest was 0.29. And the median was 0.47.

TNXP's Cyclically Adjusted PS Ratio is ranked better than
93.48% of 506 companies
in the Biotechnology industry
Industry Median: 5.565 vs TNXP: 0.37

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Tonix Pharmaceuticals Holding's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.031. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.48 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation

Tonix Pharmaceuticals Holding Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Tonix Pharmaceuticals Holding's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tonix Pharmaceuticals Holding Cyclically Adjusted PS Ratio Chart

Tonix Pharmaceuticals Holding Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cyclically Adjusted PS Ratio

Get a 7-Day Free Trial

0.62

Tonix Pharmaceuticals Holding Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cyclically Adjusted PS Ratio	Get a 7-Day Free Trial															-	-	0.52	0.62	0.39

Competitive Comparison of Tonix Pharmaceuticals Holding's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Tonix Pharmaceuticals Holding's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tonix Pharmaceuticals Holding's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tonix Pharmaceuticals Holding's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Tonix Pharmaceuticals Holding's Cyclically Adjusted PS Ratio falls into.

Tonix Pharmaceuticals Holding Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Tonix Pharmaceuticals Holding's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio	=	Share Price	/	Cyclically Adjusted Revenue per Share
	=	0.1755	/	0.48
	=	0.37

Tonix Pharmaceuticals Holding's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Tonix Pharmaceuticals Holding's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare	=	Revenue per Share	/	CPI of Mar. 2024 (Change)	*	Current CPI (Mar. 2024)
	=	0.031	/	131.7762	*	131.7762
	=	0.031

Current CPI (Mar. 2024) = 131.7762.

Tonix Pharmaceuticals Holding Quarterly Data

	Revenue per Share	CPI	Adj_RevenuePerShare
201406	0.000	100.560	0.000
201409	0.000	100.428	0.000
201412	0.000	99.070	0.000
201503	0.000	99.621	0.000
201506	0.000	100.684	0.000
201509	0.000	100.392	0.000
201512	0.000	99.792	0.000
201603	0.000	100.470	0.000
201606	0.000	101.688	0.000
201609	0.000	101.861	0.000
201612	0.000	101.863	0.000
201703	0.000	102.862	0.000
201706	0.000	103.349	0.000
201709	0.000	104.136	0.000
201712	0.000	104.011	0.000
201803	0.000	105.290	0.000
201806	0.000	106.317	0.000
201809	0.000	106.507	0.000
201812	0.000	105.998	0.000
201903	0.000	107.251	0.000
201906	0.000	108.070	0.000
201909	0.000	108.329	0.000
201912	0.000	108.420	0.000
202003	0.000	108.902	0.000
202006	0.000	108.767	0.000
202009	0.000	109.815	0.000
202012	0.000	109.897	0.000
202103	0.000	111.754	0.000
202106	0.000	114.631	0.000
202109	0.000	115.734	0.000
202112	0.000	117.630	0.000
202203	0.000	121.301	0.000
202206	0.000	125.017	0.000
202209	0.000	125.227	0.000
202212	0.000	125.222	0.000
202303	0.000	127.348	0.000
202306	0.000	128.729	0.000
202309	0.260	129.860	0.264
202312	0.064	129.419	0.065
202403	0.031	131.776	0.031

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Tonix Pharmaceuticals Holding (NAS:TNXP) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.

Tonix Pharmaceuticals Holding Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Tonix Pharmaceuticals Holding's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Tonix Pharmaceuticals Holding (Tonix Pharmaceuticals Holding) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tonix Pharmaceuticals Holding Corp (NAS:TNXP) » Definitions » Cyclically Adjusted PS Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

26 Main Street, Suite 101, Chatham, NJ, USA, 07928

Website

https://www.tonixpharma.com

Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focused on developing therapeutics and vaccines to treat and prevent human disease and alleviate suffering. its portfolio consists of the central nervous system, rare disease, immunology, and infectious disease product candidates. The CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. CNS product candidate is TNX-102 SL, a proprietary sublingual tablet formulation of cyclobenzaprine (CBP) designed for bedtime administration.

Executives

Richard Newcomb Stillwell	director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 26 MAIN STREET, SUITE 101, CHATHAM NJ 07928
Seth Lederman	director, 10 percent owner, officer: Chief Executive Officer	C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Carolyn E. Taylor	director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 26 MAIN STREET, SUITE 101, CHATHAM NJ 07928
Daniel Wintner Goodman	director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE, NEW YORK NY 10022
James Treco	director	C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., NEW YORK NY 10022
Margaret Smith Bell	director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Gregory M Sullivan	officer: Chief Medical Officer	C/O TONIX PHARMACEUTICALS HOLDINGS CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Richard H Bagger	director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE. - SUITE 1608, NEW YORK NY 10022
Adeoye Y Olukotun	director	3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
David L Grange	director
Ernest Mario	director	20 FAIRMOUNT AVENUE, P.O. BOX 445, CHATHAM NJ 07928
Jessica Edgar Morris	officer: Chief Administrative Officer	C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Bradley Saenger	officer: Chief Financial Officer	C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
John B Rhodes	director	74 FIFTH AVENUE, NEW YORK NY 10011
Samuel R Saks	director	3180 PORTER DRIVE, PALO ALTO CA 94304